Drug resistance mutations to integrase inhibitors, proteinase, and reverse transcriptase inhibitors in newly diagnosed HIV-1 infections in Hebei province, China, 2018–2022
The overall prevalence of HIV-1 PDR in Hebei is high, belonging to a moderate resistant level (5.0%-15.0%). It is necessary for us to strengthen the effective surveillance of PDR among treatment-naive patients, and we should adjust the treatment plan according to the results of PDR surveillance.
Authors
- Yan Li (ORCID: https://orcid.org/0000-0002-4655-9577)
- Dandan Sun (ORCID: https://orcid.org/0009-0001-7543-0692)
- Xinli Lu (ORCID: https://orcid.org/0000-0003-4613-2028)
- Ning An (ORCID: https://orcid.org/0000-0001-8937-4508)
- Yingying Wang (ORCID: https://orcid.org/0000-0003-4363-8779)
- Meng Liu (ORCID: https://orcid.org/0000-0001-9920-5599)
- Qi Li (ORCID: https://orcid.org/0000-0002-9422-3066)
Institutions
- Hebei Provincial Center for Disease Control and Prevention (CN)
Publication Details
- Journal
- Frontiers in Cellular and Infection Microbiology
- Published
- 2025-02-24
- DOI
- https://doi.org/10.3389/fcimb.2025.1510916
- Citations
- 7
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 9.77